Novartis’ Cemiplimab Approved in China for Moderate-to-Severe Atopic Dermatitis
Novartis (SWX: NOVN, NYSE: NVS)’s Chinese arm has announced that it has received approval from...
Drug
Johnson & Johnson’s Tremfya Gains FDA Approval for Ulcerative Colitis Treatment
Johnson & Johnson (NYSE: JNJ) announced today that the US Food and Drug Administration (FDA)...
Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US
Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food...
Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA
Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from...
Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment
Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the...
Ascentage Pharma’s Olverembatinib Shows Promise in SDH-Deficient GIST at ESMO Congress
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of...
Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis
Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...
Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...
Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...
Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy
Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...
Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...
Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...
Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China
Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...
Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...
Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...
Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors
Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...
AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute
AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...
Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss Results in Phase I Trial
Terns Pharmaceuticals Inc. (NASDAQ: TERN), a U.S.-based biotechnology company originally spun out from Eli Lilly’s...
GSK’s Nucala Shows Promise in Phase III COPD Trial, MATINEE Results Positive
GSK plc (LON: GSK, NYSE: GSK), a leading UK-based pharmaceutical company, has announced positive results...